Strategies and challenges for the next generation of antibody–drug conjugates
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies and challenges for the next generation of antibody–drug conjugates
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 16, Issue 5, Pages 315-337
Publisher
Springer Nature
Online
2017-03-17
DOI
10.1038/nrd.2016.268
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of cetuximab Fc/2 dimers by off-line CZE-MS
- (2016) Yannis-Nicolas François et al. ANALYTICA CHIMICA ACTA
- Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma
- (2016) Cong Wei et al. ANALYTICAL CHEMISTRY
- From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
- (2016) Julia Mantaj et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- One-Step Conjugation Method for Site-Specific Antibody–Drug Conjugates through Reactive Cysteine-Engineered Antibodies
- (2016) Daisuke Shinmi et al. BIOCONJUGATE CHEMISTRY
- Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
- (2016) Sujiet Puthenveetil et al. BIOCONJUGATE CHEMISTRY
- Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
- (2016) Takashi Nakada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry
- (2016) Filip S. Ekholm et al. ChemMedChem
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugates for non-oncological indications
- (2016) Renhe Liu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
- (2016) Alain Beck et al. Expert Review of Proteomics
- Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I − Optimization of separation conditions
- (2016) Morgan Sarrut et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization
- (2016) Guillaume Terral et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species
- (2016) Mélissa Excoffier et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection
- (2016) Dwight Stoll et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. II- Identification of sub-units for the characterization of even and odd load drug species
- (2016) Morgan Sarrut et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products
- (2016) Rabah Gahoual et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase
- (2016) Marta Rodriguez-Aller et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Rethinking the INN system for therapeutic antibodies
- (2016) Jérémy Pottier et al. mAbs
- Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice
- (2016) Chenguang Zhou et al. mAbs
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Resistance to Antibody–Drug Conjugates
- (2016) Frank Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
- (2016) M. L. Miller et al. MOLECULAR CANCER THERAPEUTICS
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- 2015 FDA drug approvals
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- RP-HPLC DAR Characterization of Site-Specific Antibody Drug Conjugates Produced in a Cell-Free Expression System
- (2016) Yiren Xu et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- 2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation
- (2016) Igor Dovgan et al. Scientific Reports
- Conformational Difference in Human IgG2 Disulfide Isoforms Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry
- (2015) Aming Zhang et al. BIOCHEMISTRY
- Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates
- (2015) Remon van Geel et al. BIOCONJUGATE CHEMISTRY
- Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
- (2015) Magdalena Dorywalska et al. BIOCONJUGATE CHEMISTRY
- Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins
- (2015) Hannes Merten et al. BIOCONJUGATE CHEMISTRY
- Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using Click Cycloaddition Chemistry
- (2015) Michael P. VanBrunt et al. BIOCONJUGATE CHEMISTRY
- Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody
- (2015) Pamela Thompson et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues
- (2015) Xiuling Li et al. BIOCONJUGATE CHEMISTRY
- Covalent Chemical Ligation Strategy for Mono- and Polyclonal Immunoglobulins at Their Nucleotide Binding Sites
- (2015) Diana Lac et al. BIOCONJUGATE CHEMISTRY
- CBTF: New Amine-to-Thiol Coupling Reagent for Preparation of Antibody Conjugates with Increased Plasma Stability
- (2015) Sergii Kolodych et al. BIOCONJUGATE CHEMISTRY
- Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases
- (2015) Pradman K. Qasba BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
- (2015) Gregory S. Hamilton BIOLOGICALS
- The cryptophycins as potent payloads for antibody drug conjugates
- (2015) Vishal A. Verma et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
- (2015) Taofeek Kunle Owonikoko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract 397: Rebastinib potently inhibits function of perivascular TIE2 expressing macrophagesin vitroandin vivo
- (2015) Allison Harney et al. CANCER RESEARCH
- Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)
- (2015) Dana A. Kennedy et al. CANCER RESEARCH
- A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
- (2015) A. V. Yurkovetskiy et al. CANCER RESEARCH
- Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
- (2015) B. Shor et al. CLINICAL CANCER RESEARCH
- A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
- (2015) S.-F. Yu et al. CLINICAL CANCER RESEARCH
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
- (2015) M. Damelin et al. CLINICAL CANCER RESEARCH
- Antibody-targeted drugs and drug resistance—Challenges and solutions
- (2015) LeeRon Shefet-Carasso et al. DRUG RESISTANCE UPDATES
- Emerging formats for next-generation antibody drug conjugates
- (2015) Mahendra P Deonarain et al. Expert Opinion on Drug Discovery
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides
- (2015) R. James Christie et al. JOURNAL OF CONTROLLED RELEASE
- Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
- (2015) Alain Beck et al. JOURNAL OF MASS SPECTROMETRY
- Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody–Drug Conjugates
- (2015) Brian Wiggins et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- An Immunosuppressive Antibody–Drug Conjugate
- (2015) Rongsheng E. Wang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection
- (2015) Robert E. Birdsall et al. mAbs
- The INNs and outs of antibody nonproprietary names
- (2015) Tim D. Jones et al. mAbs
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
- (2015) R. Gebleux et al. MOLECULAR CANCER THERAPEUTICS
- Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies
- (2015) C. Rouleau et al. MOLECULAR CANCER THERAPEUTICS
- Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
- (2015) A. Visintin et al. MOLECULAR CANCER THERAPEUTICS
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
- (2015) D. S. Pereira et al. MOLECULAR CANCER THERAPEUTICS
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates
- (2015) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
- (2015) Boris Shor et al. MOLECULAR IMMUNOLOGY
- Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models
- (2015) F. Lhospice et al. MOLECULAR PHARMACEUTICS
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation
- (2015) E. Erica Hong et al. MOLECULAR PHARMACEUTICS
- In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios
- (2015) Penny Bryant et al. MOLECULAR PHARMACEUTICS
- Sensitive ELISA Method for the Measurement of Catabolites of Antibody–Drug Conjugates (ADCs) in Target Cancer Cells
- (2015) Paulin L. Salomon et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers
- (2015) Bryan C. Murray et al. NATURAL PRODUCT REPORTS
- TP53 loss creates therapeutic vulnerability in colorectal cancer
- (2015) Yunhua Liu et al. NATURE
- Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
- (2015) Sophie M. Lehar et al. NATURE
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading
- (2015) Pavel Strop et al. NATURE BIOTECHNOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving Strategies for Target Selection for Antibody-Drug Conjugates
- (2015) Marc Damelin et al. PHARMACEUTICAL RESEARCH
- Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate
- (2015) Julien Marcoux et al. PROTEIN SCIENCE
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
- (2015) Laura R. Saunders et al. Science Translational Medicine
- Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs
- (2015) Robert V. Kolakowski et al. TETRAHEDRON LETTERS
- A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
- (2015) Antoine Maruani et al. Nature Communications
- A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
- (2015) S Y Kim et al. Blood Cancer Journal
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency
- (2015) Roger R. Beerli et al. PLoS One
- Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR Distribution Assessment
- (2014) François Debaene et al. ANALYTICAL CHEMISTRY
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Preparation of Well-Defined Antibody-Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide-Alkyne Cycloadditions
- (2014) Xiuru Li et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers
- (2014) James T. Patterson et al. BIOCONJUGATE CHEMISTRY
- Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
- (2014) L. Nathan Tumey et al. BIOCONJUGATE CHEMISTRY
- Long-Term Stabilization of Maleimide–Thiol Conjugates
- (2014) Shaun D. Fontaine et al. BIOCONJUGATE CHEMISTRY
- Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
- (2014) Erik S. Zimmerman et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugation through Glycoengineering
- (2014) Qun Zhou et al. BIOCONJUGATE CHEMISTRY
- Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes
- (2014) Penelope M. Drake et al. BIOCONJUGATE CHEMISTRY
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Exploring the effects of linker composition on site-specifically modified antibody–drug conjugates
- (2014) Aaron E. Albers et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- A Chemically Defined Trifunctional Antibody-Cytokine-Drug Conjugate with Potent Antitumor Activity
- (2014) T. List et al. MOLECULAR CANCER THERAPEUTICS
- Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
- (2014) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Methods to Make Homogenous Antibody Drug Conjugates
- (2014) Toni Kline et al. PHARMACEUTICAL RESEARCH
- In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
- (2014) Dowdy Jackson et al. PLoS One
- A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
- (2014) A. E. Prota et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/ -ketoglutarate-dependent dioxygenase
- (2014) A. S. Eustaquio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A general approach to site-specific antibody drug conjugates
- (2014) Feng Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
- (2014) P. Muller et al. Cancer Immunology Research
- Time Resolved Native Ion-Mobility Mass Spectrometry to Monitor Dynamics of IgG4 Fab Arm Exchange and “Bispecific” Monoclonal Antibody Formation
- (2013) François Debaene et al. ANALYTICAL CHEMISTRY
- Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation
- (2013) Nicole M. Okeley et al. BIOCONJUGATE CHEMISTRY
- A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
- (2013) Scott C. Jeffrey et al. BIOCONJUGATE CHEMISTRY
- Why is it so difficult to use gemtuzumab ozogamicin?
- (2013) BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Approval of the first biosimilar antibodies in Europe
- (2013) Alain Beck et al. mAbs
- 8thAnnual European Antibody Congress 2012
- (2013) Alain Beck et al. mAbs
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Antibody-drug conjugates
- (2013) Alain Beck et al. mAbs
- Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion
- (2013) Elsa Wagner-Rousset et al. mAbs
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers
- (2013) S. V. Govindan et al. MOLECULAR CANCER THERAPEUTICS
- The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
- (2013) Hans-Peter Gerber et al. NATURAL PRODUCT REPORTS
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- PK assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine
- (2013) Randall Dere et al. Bioanalysis
- Characterization of Therapeutic Antibodies and Related Products
- (2012) Alain Beck et al. ANALYTICAL CHEMISTRY
- Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
- (2012) Kathrin Zuberbühler et al. CHEMICAL COMMUNICATIONS
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Design and Application of Antibody Cysteine Variants
- (2010) Vladimir Voynov et al. BIOCONJUGATE CHEMISTRY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
- (2009) Ruoping Tang et al. BMC CANCER
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
- (2009) Aran F Labrijn et al. NATURE BIOTECHNOLOGY
- Editorial [Hot Topic: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic(Guest Editor: Alain Beck)]
- (2008) A. Beck et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
- (2008) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started